New Haven’s Biohaven has earned FDA “Fast Track” designation for its drug to treat muscle loss in spinal muscular atrophy patients.
Biohaven’s drug, taldefgrobep alfa, is scheduled for a Phase 3 clinical trial and had previously earned orphan drug designation for its use in spinal muscular atrophy, a rare and progressively debilitating motor-neuron disease.